Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice

Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and efficacy of the combination of CDKIs plus radiotherapy...

Full description

Bibliographic Details
Main Authors: Ambrogio Gagliano, Angela Prestifilippo, Ornella Cantale, Gianluca Ferini, Giacomo Fisichella, Paolo Fontana, Dorotea Sciacca, Dario Giuffrida
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
metastatic breast cancer (mbc)
cyclin-dependent kinase inhibitors (CDKi)
palbociclib
radiotherapy
toxicity
ribociclib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.643155/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.643155/full

Similar Items